Stock Quotes in this Article: ALXN, ARIA, BMRN, HUM, NWSA, TJX, VPHM, ZUMZ

WINDERMERE, Fla. (Stockpickr) -- At Stockpickr, we track daily portfolios of stocks that are hitting new 52-week highs and 52-week lows.

When you see a stock that’s hitting new 52-week highs it often means that the uptrend is very strong and the buyers are in full control (and the opposite for stocks setting new 52-week lows), and momentum traders often look at the 52-week high lists to find new trading ideas. Keep in mind, though, that new highs can also mean that the stock is overbought or has run up too far too fast.

>>5 Big Stocks to Trade for Gains

That’s why it’s important to combine a number of technical indicators like volume, price, trend and momentum indicators such as RSI before you make an investing or trading decision. Combine all of those things with fundamental trends, disciple and sound money management and you will be well on your way to investment success.

Let's take a closer look at several stocks that hit new 52-week highs today.

ViroPharma

ViroPharma (VPHM) is a global biotechnology company focused on the development and commercialization of products that address diseases, with a focus on products used by physician specialists or in hospital settings. This stock is trading up 0.12% to $28.28 in recent trading after hitting a 52-week high of $29.10 earlier today.

Today’s Range: $28.66-$29.10

52-Week Range: $14.62-$28.79

Volume: 1.1 million

Three-Month Average Volume: 1 million

ViroPharma has a market cap of $2.03 billion and an enterprise value of $1.68 billion. This stock trades at a trailing price-to-earnings of 19.29 and a forward price-to-earnings of 19.15. Its estimated growth rate for this year is -4%, and for next year it’s pegged at 4.2%. The current short interest as a percentage of the float for ViroPharma is rather high at 12.5%.

Shares of VPHM are hitting new highs today after the company said it expects product sales of $600 million to $660 million this year, which is higher than previous Wall Street estimates.

>>8 Stocks Rising on Huge Volume

From a technical standpoint, VPHM has started to flirt with a breakout trade today since the stock was briefly trading above some near-term overhead resistance at $28.34 on solid volume. Traders should now look for a sustained high-volume move and close above $28.34 to signal that this stock wants to break out and make a run at its next significant overhead resistance level near $40.

Look for a close today on VPHM that’s near its daily highs and look for volume that’s well above 1 million shares. If we get that action, then traders should look for long biased trades as long as VPHM continues to trend above $28.34.

BioMarin Pharmaceutical

BioMarin Pharmaceutical (BMRN) develops and commercializes pharmaceuticals for serious diseases and medical conditions. This stock is trading up 1.1% to $36.00 in recent trading after hitting a 52-week high of $36.13 earlier in the day.

Today’s Range: $35.47-$36.13

52-Week Range: $23.09-$35.94

Volume: 225,000

Three-Month Average Volume: 803,464

BioMarin Pharmaceutical has a market cap of $4.11 billion and an enterprise value of $4.19 billion. This stock trades at a price-to-sales of 9.34 and a price-to-book of 5.25. Its estimated growth rate for this year is -120.2%, and for next year it’s pegged at 8.6%. The current short interest as a percentage of the float for BioMarin Pharmaceutical is notable at 6.8%.

From a technical standpoint, BMRN has started to trigger a major breakout trade today now that the stock is taking out some past overhead resistance at $35.47 to $35.56. The only thing lacking on this breakout is heavy volume, since only 225,000 shares have traded versus its average volume of 803,463.

That said, price always trumps volume, so if BMRN can sustain a move and close over $35.56, then it has a shot at trading back toward its all-time high at $40. Traders should continue to monitor the volume in the coming days to see if it firms up, and continue to look for long-biased trades as long as BMRN continues its trend above $35.47 to $35.56.

As of the most recently reported quarter, BioMarin is one of the top holdings in Columbia Wanger Asset Management's portfolio.

Zumiez

Zumiez (ZUMZ) is a mall-based specialty retailer of action sports related apparel, footwear, equipment and accessories operating under the Zumiez brand name. This stock is trading up 1.5% at $31.44 in recent trading after hitting a 52-week high of $31.63 earlier in the day.

Today’s Range: $30.47-$31.63

52-Week Range: $15.85-$30.96

Volume: 600,000

Three-Month Average Volume: 540,881

Zumiez has a market cap of $965.9 million and an enterprise value of $826.3 million. The stock trades at a trailing price-to-earnings of 28.59 and a forward price-to-earnings of 22.66. Its estimated growth rate for this year is 31.8%, and for next year it’s pegged at 18.1%. The current short interest as a percentage of the float for Zumiez is extremely high at 22.4%.

>>5 Large-Cap Stocks That Could Pop in 2012

From a technical standpoint, ZUMZ has started to trigger a major breakout trade today now that this stock is moving above some past overhead resistance at $30.40 to $30.90 with solid volume.

Traders should now look for a sustained high-volume move and close above those levels to signal that ZUMZ wants to challenge its 2010 high of $33.13. Look for ZUMZ to close near its daily highs and for volume to be well above 540,881 shares.

Ariad Pharmaceuticals

Ariad Pharmaceuticals (ARIA) is a biopharmaceutical company focused on the discovery and development of drugs to provide therapeutic intervention in treating human diseases at the cellular level. This stock is trading up 2.8% at $13.59 in recent trading after hitting a 52-week high of $13.66 earlier in the day.

Today’s Range: $13.20-$13.66

52-week Range: $5.06-$13.50

Volume: 1.8 million

Three-Month Average Volume: 3.15 million

Ariad Pharmaceuticals has a market cap of $1.80 billion and an enterprise value of $1.68 billion. The stock trades at a price-to-sales of 68.13 and a price-to-book of 65.40. Its estimated growth rate for this year is 134.5%, and for next year it’s pegged at 19.4%. The current short interest as a percentage of the float for Ariad Pharmaceuticals stands at 12.8%.

From a technical standpoint, ARIA recently triggered a breakout trade when the stock took out some past overhead resistance at $12.50 with solid volume. The stock is now triggering another big breakout trade, with shares moving above some major overhead resistance from July at $13.50.

Traders should now look for a sustained high-volume move and close above $13.50 to signal that ARIA wants to trend significantly higher. Look for volume that’s near or above its average action of 3.15 million shares.

Ariad shows up on a list of 10 Biotech Stocks Loved and Hated by Wall Street's Top Investment Pros for the most recently reported quarter.

Humana

Humana (HUM) is a health and supplemental benefits company. This stock is trading up 2.5% at $94.03 in recent trading after hitting a 52-week high of $94.85 earlier in the day.

Today’s Range: $91.75-$92.85

52-Week Range: $55.68-$91.76

Volume: 1.6 million

Three-Month Average Volume: 1.56 million

Humana has a market cap of $15.09 billion and an enterprise value of $5.08 billion. The stock trades at a trailing price-to-earnings of 11.75 and a forward price-to-earnings of 36.46. Its estimated growth rate for this year is 20.2%, and for next year it’s pegged at -5.5%. The current short interest as a percentage of the float for Humana is very low at 1.3%.

From a technical standpoint, HUM has started to trigger a big breakout trade today now that the stock has started to trade above some past overhead resistance at $90.51 with volume. Market players should now look for HUM to close near its daily highs and volume to register well above 1. 56 million shares.

Volume at last check is already above that level, so look for a strong close to conform that this stock wants to make a run at $100 in the near future.

Humana, one of TheStreet Ratings' top-rated managed health care stocks, shows up on a recent list of 9 Defensive Stocks to Play and was one of the 10 Best-Performing S&P 500 Stocks of 2011.

TJX

TJX (TJX) is an off-price apparel and home fashions retailer in the U.S. and worldwide. This stock is trading up 0.45% at $66.62 in recent trading after hitting a 52-week high of $66.95 earlier in the day.

Today’s Range: $66.03-$66.95

52-Week Range: $45.26-$66.55

Volume: 1.1 million

Three-Month Average Volume: 2.75 million

TJX has a market cap of $25.19 billion and an enterprise value of $24.77 billion. The stock trades at a trailing price-to-earnings of 19.2 and a forward price-to-earnings of 14.94. Its estimated growth rate for this year is 13.4%, and for this year it’s pegged 12.6%. The current short interest as a percentage of the float for TJX Companies is extremely low at 1.7%.

From a technical standpoint, TJX has started to trigger a breakout trade today now that the stock is continuing its move above some past overhead resistance at $65.50. The high for the stock was $66.55 yesterday and volume was very strong with over 4.3 million shares trading hands. The push higher in TJX today has moved the stock into all-time high territory, which is bullish price action.

Market players should continue to look for long biased trades as long as TJX continues to trend above $65.50.

TJX shows up on recent lists of Cramer's 7 Stocks for Your Buy List and Goldman Sachs' Consumer Stock Best Buys for 2012.

News Corp.

News Corp. (NWSA) is a diversified global media company. This stock is trading down 0.5% at $18.39 in recent trading after hitting a 52-week high of $18.66 earlier in the day.

Today’s Range: $18.32-$18.66

52-Week Range: $13.38-$18.52

Volume: 5,440,000

Three-Month Average Volume: 19,583,100

News Corp. has a market cap of $46.3 billion and an enterprise value of $50.62 billion. The stock trades at a trailing price-to-earnings of 18.03 and a forward price-to-earnings of 10.93. Its estimated growth rate for this year is 16.9%, and for next year it’s pegged at 21.7%. The current short interest as a percentage of the float for News Corp is very low at 2.2%.

From a technical standpoint, NWSA recently triggered a breakout trade when the stock moved above some past overhead resistance at $18 to $18.24.

Market players should continue to look for long biased trades as long as NWSA can continue its current trend above $18 to $18.24. Any future move below those breakout levels with volume would mean that this recent breakout is a failed technical move.

News Corp., one of TheStreet Ratings' top-rated media stocks, shows up on a recent list of 7 U.S. Stock Picks for 2012 From Addison Capital. It was also featured recently in "5 Stocks Hedge Funds Favor for 2012."

Alexion Pharmaceuticals

Alexion Pharmaceuticals (ALXN) is a biopharmaceutical company engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with severe and life-threatening disease states, including those in the therapeutic areas of hematology, nephrology (including transplant rejection), neurology, ophthalmology and cancer. This stock is trading up 2.2% at $74 in recent trading after hitting a 52-week high of $74.44 earlier in the day.

Today’s Range: $72.00-$74.44

52-Week Range: $40.04-$73.05

Volume: 464,000

Three-Month Average Volume: 1.2 million

Alexion Pharmaceuticals has a market cap of $13.61 billion and an enterprise value of $12.96 billion. The stock trades at a trailing price-to-earnings of 91.22 and a forward price-to-earnings of 44.83. Its estimated growth rate for this year is 46.1%, and for next year it’s pegged at 26.2%. The current short interest as a percentage of the float for Alexion Pharmaceuticals is very low at 1.5%.

From a technical standpoint, ALXN recently triggered a breakout trade when the stock took out some past overhead resistance at $70.50 to $72.50. This move today in the stock has pushed shares into all-time high territory, which is bullish for any stock.

Market players should continue to look for long biased trades as long as ALXN can continue to trend above $70.50 to $72.50.

Alexion is one of TheStreet Ratings' top-rated biotechnology stocks.

To see more stocks hitting new 52-week highs today, check out the Stocks Hitting New 52-Week Highs portfolio on Stockpickr.

-- Written by Roberto Pedone in Winderemere, Fla.

RELATED LINKS:

>>5 Stocks With Notable Insider Buying

>>10 Top S&P 500 Stocks for 2012

>>3 Housing Stocks for a 2012 Rebound

 

Follow Stockpickr on Twitter and become a fan on Facebook.

At the time of publication, author had no positions in stocks mentioned.

Roberto Pedone, based out of Windermere, Fla., is an independent trader who focuses on stocks, options, futures, commodities and currencies. He is also an outside contributor to Beconequity.com and maintains the website Maddmoney.net, which he sold to Blue Wave Advisors in 2008. Roberto studied International Business at The Milwaukee School of Engineering, and he spent a year overseas studying business in Lubeck, Germany.